BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers

• Published in: The Journal of clinical investigation Vol. 131; no. 2; pp. 1 - 11
• Main Authors: Rivas, Magali Noval, Ebinger, Joseph E, Wu, Min, Sun, Nancy, Braun, Jonathan, Sobhani, Kimia, Van Eyk, Jennifer E, Cheng, Susan, Arditi, Moshe
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 19.01.2021
• Subjects: Adult; BCG vaccination; BCG Vaccine - immunology; BCG Vaccine - pharmacology; Biomedical research; Clinical Medicine; Clinical trials; Cohort Studies; Coronaviridae; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - prevention & control; Disease; Epigenetics; Female; Fever; Health aspects; Health care; Health Personnel; Humans; Immunity, Innate; Immunoglobulin G; Infections; Influenza; Influenza Vaccines - immunology; Influenza Vaccines - pharmacology; Longitudinal Studies; Los Angeles - epidemiology; Male; Medical personnel; Meningococcal Vaccines - immunology; Meningococcal Vaccines - pharmacology; Middle Aged; Multivariate Analysis; Pandemics; Pneumococcal Vaccines - immunology; Pneumococcal Vaccines - pharmacology; Public health; Retrospective Studies; Seroconversion; Seroepidemiologic Studies; Serology; Severe acute respiratory syndrome coronavirus 2; Tuberculosis; Vaccination; Vaccines; Viral infections; Los Angeles; United States; Los Angeles County California; United States > US; COVID-19; Innate immunity; Vaccines

BACKGROUNDSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective inn...